| Treatment of endometriosis with transvaginal ultrasound-guided drainage under GnRH analogues and recombinant interleukin-2 left in the cysts. | |
| | |
MedLine Citation:
|
PMID: 16244488 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: To analyze the therapeutic results of one dose of 3 million IU of recombinant interleukin-2 (rIL-2) left intracyst (group I) versus two doses with a 1-month interval (group II) after transvaginal ultrasound (US)-guided drainage of endometriomas under the effect of GnRH analogues. METHODS: Prospective and randomized clinical trial (helped by a random number table) at a University Hospital. Twenty-four consecutive patients with endometriomas initially sent to us for laparotomy and conservative surgery for endometriosis were included. INTERVENTIONS: Treatment with GnRH analogues every 28 days, 3 doses. Under their effect, one or two transvaginal US-guided punctures were performed in order to aspirate the endometriomas, and 3 million IU of rIL-2 were left in the aspirated cysts each time. MAIN OUTCOME MEASURES: Clinical results: two menstruations after GnRH analogues. Other secondary outcome measures were: the time until recurrence of cysts, symptoms and CA-125 >35 U/ml, and the need for further medical or surgical treatment. RESULTS: They were moderate or good in >50% of cases with one drainage and one dose of 3 million IU of rIL-2 intracyst, but were better with a second drainage and two doses of rIL-2 (25 vs. 58.3% 'good results'). There were fewer recurrences and the interval before recurrence was longer after two doses but differences were not significant. Six patients from group I (50%) and 3 from group II (25%) needed laparotomy and conservative surgery at 17.5 +/- 8.7 months (total time of follow-up = 33 +/- 8.8 months). CONCLUSIONS: Treatment of endometriomas with transvaginal US-guided drainage and rIL-2 left in the cysts under endometrial suppressive therapy with GnRH analogues has beneficial effects, improving clinical manifestations and avoiding some surgical therapies. The use of a higher dose of rIL-2 does not produce better results, whereas drainage + rIL-2 twice does. |
| | |
Authors:
|
Pedro Acién; Gloria Pérez-Albert; Francisco J Quereda; Marisa Sánchez-Ferrer; Ana García-Almela; Irene Velasco |
Related Documents
:
|
9352418 - Autoimmune progesterone dermatitis: effective prophylactic treatment with danazol. 8692508 - Natural cytotoxicity and gnrh agonist administration in advanced endometriosis: positiv... 8557138 - Danazol versus a gonadotropin-releasing hormone agonist as preoperative preparation for... 8725758 - Endometrial resection vs. abdominal hysterectomy for menorrhagia. correlated sample ana... 11080238 - Late onset heterozygous ornithine transcarbamylase deficiency mimicking complex partial... 21605518 - Laparoscopic nephrectomy in patients undergoing hemodialysis treatment. |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2005-10-21 |
Journal Detail:
|
Title: Gynecologic and obstetric investigation Volume: 60 ISSN: 0378-7346 ISO Abbreviation: Gynecol. Obstet. Invest. Publication Date: 2005 |
Date Detail:
|
Created Date: 2005-10-31 Completed Date: 2006-01-20 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7900587 Medline TA: Gynecol Obstet Invest Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 224-31 Citation Subset: IM |
Copyright Information:
|
Copyright 2005 S. Karger AG, Basel. |
Affiliation:
|
Service of Obstetrics and Gynecology, San Juan University Hospital and Department of Gynecology, School of Medicine, Miguel Hernandez University, Campus of San Juan, Alicante, Spain. acien@umh.es |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Topical Adult Drainage / methods Endometriosis / drug therapy, pathology, therapy*, ultrasonography Female Gonadotropin-Releasing Hormone / agonists Humans Interleukin-2 / administration & dosage, therapeutic use Recombinant Proteins / therapeutic use Treatment Outcome Triptorelin / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Interleukin-2; 0/Recombinant Proteins; 33515-09-2/Gonadotropin-Releasing Hormone; 57773-63-4/Triptorelin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Intravenous TPA for very old stroke patients.
Next Document: A rapidly growing paraurethral myoma with profuse bleeding from a mucosal vessel: report of a case.